Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | SPR | P35270 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102308 | 1.00 | SETD7 (0.65) | SETD7HTTL3MBTL1KDM4EPKM | |
| SCHEMBL31587841 | 0.90 | SETD7 (0.65) | SETD7HTTL3MBTL1GHSRSPR | |
| SCHEMBL28878082 | 0.88 | SETD7 (0.66) | SETD7HTTL3MBTL1GHSRSPR | |
| SCHEMBL28878080 | 0.88 | SETD7 (0.66) | SETD7HTTL3MBTL1GHSRSPR | |
| SCHEMBL14121618 | 0.88 | SETD7 (0.52) | SETD7HTTL3MBTL1KDM4EPKM | |
| SCHEMBL14121985 | 0.88 | SETD7 (0.52) | SETD7HTTL3MBTL1KDM4EPKM | |
| SCHEMBL1385650 | 0.87 | SETD7 (0.51) | SETD7KDM4EPKMUSP30ROCK2 | |
| SCHEMBL19284223 | 0.86 | SETD7 (0.67) | SETD7KDM4EGHSRGPR119MEN1 | |
| SCHEMBL30312896 | 0.84 | SETD7 (0.58) | SETD7HTTL3MBTL1GHSRMEN1 | |
| SCHEMBL19284204 | 0.83 | SETD7 (0.61) | SETD7HTTMEN1KMT2APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2170866-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | SETD7 1332/4885HTT 163/4885L3MBTL1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.